-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 26, the sixth batch of national-organized centralized drug procurement (insulin special) officially opened bids in Shanghai, and the results of the proposed selection were announced on the same day
.
It is reported that the sixth batch of national insulin drug centralized procurement announced 45 products to be selected, and the average price of drugs was reduced by 47.
67%, with a maximum of more than 70%
.
The bid-winning companies include 8 domestic pharmaceutical companies: Yifan Biological, Tianmai Biological, United Laboratories, Tonghua Dongbao, Wanbang Pharmaceutical, Dongyang Yangtze Pharmaceutical, Ganli Pharmaceutical, Zhejiang Hisun; 3 multinational pharmaceutical companies: Novo Nuo Germany, Eli Lilly, Sanofi
.
Judging from the results of the proposed selection, among the domestic insulin companies, Ganli Pharmaceutical won the bid for all 6 products; United Lab won the bid for 6 products; Tonghua Dongbao won the bid for 5 products
.
Among foreign insulin companies, Novo Nordisk won the bid for 7 products; Eli Lilly won the bid for 5 products; Sanofi won the bid for 2 products
.
Judging from the current outflow of insulin price cuts, companies generally have a drop of more than 50%, and the highest is more than 70%
.
It is worth noting that the decline of Ganli Pharmaceutical is generally more than 60%.
Among them, three products of protamine and human insulin mixed injection (30R), insulin glargine, and insulin aspart are selected in the three purchasing groups with one order.
The quotations are respectively 17.
89 yuan/piece, 48.
71 yuan/piece, and 19.
98 yuan/piece
.
Hisun Pharmaceutical's insulin aspart injection dropped by 67%, and Baitong/Yifan and Tianmaida dropped by about 55%
.
In addition, among the 6 purchasing groups, among the second-generation insulins, the lowest proposed winning bid price for mealtime human insulin and basal human insulin were both 22.
32 yuan/piece, a decrease of 55%, and the companies to be selected were Yifan Bio; the lowest pre-mixed human insulin The proposed bid price is 17.
89 yuan/piece, a decrease of 64%, and the proposed company is Ganli Pharmaceutical; and among the three generations of insulin, the lowest proposed bid price for meal insulin analogues is 19.
98 yuan/piece, a decrease of 72%.
It is Ganli Pharmaceutical; the lowest proposed winning bid price of basal insulin analog is 48.
71 yuan/branch, a drop of 63%, and the proposed company is Ganli Pharmaceutical; the lowest proposed winning bid price of premixed insulin analog is 18.
89 yuan/branch, a drop of up to 74%, The proposed company is Eli Lilly and Company
.
The special centralized procurement cycle of insulin is 2 years.
It is determined according to the volume of the medical institutions participating in the procurement.
This time, the country’s first-year procurement demand totaled 212 million units
.
Among them, 90 million second-generation insulins and 124 million third-generation insulins
.
Regarding this centralized insulin procurement, Tonghua Dongbao said that centralized procurement is both a challenge and an opportunity for enterprises.
It will drive the long-term development of high-quality national enterprises, accelerate the process of insulin localization, and promote enterprise innovation and transformation
.
The successful bidding of Tonghua Dongbao insulin central procurement has laid the foundation for the stable development of the company in the future
.
With the continuous commercialization of enterprise research projects and the effective implementation of innovative transformation strategies, Tonghua Dongbao will usher in a new leap
.
It is understood that with the announcement of the results of the proposed election, the stock prices of various companies have also risen.
For example, the stock price of Ganli Pharmaceutical rose by more than 7%; Yifan Pharmaceuticals, as an agent of Polish Baitong's insulin products, this morning, the daily limit of Yifan Pharmaceuticals was reported.
It closed at 18.
8 yuan
.
According to the industry, unlike the previous five centralized procurements, insulin is a biological drug in this centralized procurement.
This also marks that the scope of centralized drug procurement organized by the state has expanded from chemical drugs to the field of biological drugs, which will further reduce the burden of medication for patients
.
This time is a special purchase of insulin.
Based on the demand from 32,000 medical institutions, the demand for centralized insulin collection is about 200 million, involving an amount of about 17 billion yuan, which is related to the well-being of 10 million insulin patients nationwide.
.
Some analysts said that the introduction of insulin products into the country can not only reduce the economic burden of diabetic patients, but also increase the compliance of patients with insulin to a certain extent
.
.
It is reported that the sixth batch of national insulin drug centralized procurement announced 45 products to be selected, and the average price of drugs was reduced by 47.
67%, with a maximum of more than 70%
.
The bid-winning companies include 8 domestic pharmaceutical companies: Yifan Biological, Tianmai Biological, United Laboratories, Tonghua Dongbao, Wanbang Pharmaceutical, Dongyang Yangtze Pharmaceutical, Ganli Pharmaceutical, Zhejiang Hisun; 3 multinational pharmaceutical companies: Novo Nuo Germany, Eli Lilly, Sanofi
.
Judging from the results of the proposed selection, among the domestic insulin companies, Ganli Pharmaceutical won the bid for all 6 products; United Lab won the bid for 6 products; Tonghua Dongbao won the bid for 5 products
.
Among foreign insulin companies, Novo Nordisk won the bid for 7 products; Eli Lilly won the bid for 5 products; Sanofi won the bid for 2 products
.
Judging from the current outflow of insulin price cuts, companies generally have a drop of more than 50%, and the highest is more than 70%
.
It is worth noting that the decline of Ganli Pharmaceutical is generally more than 60%.
Among them, three products of protamine and human insulin mixed injection (30R), insulin glargine, and insulin aspart are selected in the three purchasing groups with one order.
The quotations are respectively 17.
89 yuan/piece, 48.
71 yuan/piece, and 19.
98 yuan/piece
.
Hisun Pharmaceutical's insulin aspart injection dropped by 67%, and Baitong/Yifan and Tianmaida dropped by about 55%
.
In addition, among the 6 purchasing groups, among the second-generation insulins, the lowest proposed winning bid price for mealtime human insulin and basal human insulin were both 22.
32 yuan/piece, a decrease of 55%, and the companies to be selected were Yifan Bio; the lowest pre-mixed human insulin The proposed bid price is 17.
89 yuan/piece, a decrease of 64%, and the proposed company is Ganli Pharmaceutical; and among the three generations of insulin, the lowest proposed bid price for meal insulin analogues is 19.
98 yuan/piece, a decrease of 72%.
It is Ganli Pharmaceutical; the lowest proposed winning bid price of basal insulin analog is 48.
71 yuan/branch, a drop of 63%, and the proposed company is Ganli Pharmaceutical; the lowest proposed winning bid price of premixed insulin analog is 18.
89 yuan/branch, a drop of up to 74%, The proposed company is Eli Lilly and Company
.
The special centralized procurement cycle of insulin is 2 years.
It is determined according to the volume of the medical institutions participating in the procurement.
This time, the country’s first-year procurement demand totaled 212 million units
.
Among them, 90 million second-generation insulins and 124 million third-generation insulins
.
Regarding this centralized insulin procurement, Tonghua Dongbao said that centralized procurement is both a challenge and an opportunity for enterprises.
It will drive the long-term development of high-quality national enterprises, accelerate the process of insulin localization, and promote enterprise innovation and transformation
.
The successful bidding of Tonghua Dongbao insulin central procurement has laid the foundation for the stable development of the company in the future
.
With the continuous commercialization of enterprise research projects and the effective implementation of innovative transformation strategies, Tonghua Dongbao will usher in a new leap
.
It is understood that with the announcement of the results of the proposed election, the stock prices of various companies have also risen.
For example, the stock price of Ganli Pharmaceutical rose by more than 7%; Yifan Pharmaceuticals, as an agent of Polish Baitong's insulin products, this morning, the daily limit of Yifan Pharmaceuticals was reported.
It closed at 18.
8 yuan
.
According to the industry, unlike the previous five centralized procurements, insulin is a biological drug in this centralized procurement.
This also marks that the scope of centralized drug procurement organized by the state has expanded from chemical drugs to the field of biological drugs, which will further reduce the burden of medication for patients
.
This time is a special purchase of insulin.
Based on the demand from 32,000 medical institutions, the demand for centralized insulin collection is about 200 million, involving an amount of about 17 billion yuan, which is related to the well-being of 10 million insulin patients nationwide.
.
Some analysts said that the introduction of insulin products into the country can not only reduce the economic burden of diabetic patients, but also increase the compliance of patients with insulin to a certain extent
.
